What is the mechanism of action for LABAs?

Long-acting beta-agonists (LABAs) primarily facilitate long-term airway relaxation through their action on beta-2 adrenergic receptors in the smooth muscle of the airways. When these receptors are stimulated by LABAs, it leads to prolonged bronchodilation, which helps to maintain open airways and prevent bronchoconstriction over an extended period.

LABAs are often used in combination with inhaled corticosteroids as part of a comprehensive asthma management plan, particularly for patients who need additional control over their symptoms beyond the use of short-acting bronchodilators. This sustained action is beneficial for managing chronic symptoms and preventing nighttime awakenings due to asthma.

In contrast, immediate bronchodilation is characteristic of short-acting beta-agonists (SABAs), which provides quick relief but does not offer the long-term benefits. The reduction of airway inflammation is primarily the role of inhaled corticosteroids rather than LABAs. While discussing mucus production, it's important to note that LABAs do not specifically inhibit mucus production; that function is more related to other therapeutic classes like anticholinergics or corticosteroids.